Please login to the form below

Not currently logged in
Email:
Password:

Merck/ Parexel biosimilar alliance

Merck and Parexel have announced a strategic alliance to develop biosimilar candidates

Merck and Parexel have announced a strategic alliance to develop biosimilar candidates.

The agreement will see Parexel, a contract research organisation (CRO) with a focus on the biopharma industry, provide Merck  with access to global clinical development services for designated biosimilar candidates. The biosimilar candidates span several therapy areas.

A dedicated unit of Merck BioVentures,  the division of Merck focused on the development of biosimilars, will also be established within Parexel.

Financial details of the deal were not disclosed.

"Through this agreement, Merck BioVentures has secured broad strategic access to Parexel's proven biosimilar clinical development experience," said Michael Kamarck, president , Merck BioVentures. "This agreement positions Merck BioVentures for success with an industry leading partner that has the expertise and resources to conduct clinical development of our diverse portfolio of candidates to allow timely delivery of products to the marketplace."

Josef von Rickenbach, chairman and CEO of Parexel, was also positive about the agreement: "We are committed to working with Merck BioVentures to assist in advancing its biosimilar portfolio in this rapidly developing market segment for the benefit of patients worldwide."

13th January 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Evoke Kyne

Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...

Latest intelligence

Biosimilars and beyond: innovating for improved patient outcomes
How Europe’s biosimilar landscape has rapidly evolved over the last two decades, bringing biological medicines to more patients than ever before...
World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...